Amanta Healthcare IPO: Price Band, Analysis, Allotment And GMP

Amanta Healthcare IPO - Company Analysis

Amanta Healthcare IPO, a Mainboard IPO, is a bookbuilding issue of Rs. 126 Cr (~1 crore Shares) by Amanta Healthcare Ltd., which was incorporated in 1994 and focuses on the development, production, and distribution of a wide range of sterile liquid products, particularly parenteral products, that are packaged in plastic containers using the technologies of Aseptic Blow-Fill-Seal ("ABFS") and Injection Stretch Blow Moulding ("ISBM"). The business also produces medical equipment.

The company produces respiratory care items, ophthalmic solutions, diluents, and IV fluids, as well as fluid therapy formulations. In the medical device market, it also sells eye lubricants, first aid supplies, and irrigation treatments.

Three business areas are used by the corporation to promote its goods: national sales, international sales, and product partnerships with different pharmaceutical enterprises in India and abroad.

Through 320 distributors and stockists, the company markets more than 45 generic items under its own name in India and exports its branded products to 21 Countries.

 

Amanta Healthcare IPO Details

The Amanta IPO open date is from Sep 01 to Sep 03, with IPO allotment on Sep 04, refund initiation on Sep 08, 2025.

The Rs. 126 Cr mainline IPO comprises a wholly fresh issue of 1 crore Shares.

The Amanta Healthcare IPO listing date might be on Tuesday, 09 September 2025, and it will be listed at the BSE and NSE. The Amanta Healthcare IPO price band is Rs. 120 to Rs. 126 for each Share. 

Events	Date
IPO Opening Date	Sep 01, 2025
IPO Closing Date	Sep 03, 2025
IPO Allotment Date	Sep 04, 2025
Refund Initiation	Sep 08, 2025
Tentative IPO Listing Date	Sep 09, 2025

 

Amanta Healthcare IPO: Hidden Facts

• Overreliance on Two International Clients: Exports from FY24 were concentrated with a single US and Latin American client for more than half. Losing either customer would severely impact revenue.

• Promoter-Linked Companies Deals: Some raw material purchases, along with sterilisation and logistics, are procured from sterilisation and logistics. There are family businesses that are promoter-related. This creates a conflict of interest.

• USFDA Observations: There were a few minor USFDA concerns with one sterile injectable facility in the past and might create a concern for exports.

• Hidden Debt: The company seems debt-free, but appears to have more than 58 crores of concealed lease liabilities.

• Panama Subsidiary: Sales for Latin America are channelled through a Panama subsidiary.

• Pollution Board Case: Pending issues with the Gujarat Pollution Control Board for the discharge of wastewater, which carry small fines but can severely restrict licensing for repeat issues.

• Tax dispute: Approximately Rs. 14 Cr was demanded by the Income Tax Department. The business marked it as "disputed." IPO proceeds may be used if they are lost.

• Hidden Promoter Pledge: While labelled as ‘no pledge’, the records of the firm suggest a 2023 encumbrance on a personal loan of a promoter. This indicates a hidden share pledge.

 

Industry Outlook

By FY28, the healthcare delivery sector is expected to reach approximately Rs 9.4-9.8 trillion.

If you want to apply for the IPO, click to open a Demat Account.

 

 

Company Financial 

(Amount in Cr)

Period	31 Mar 2025	31 Mar 2024	31 Mar 2023
Total Assets	381.76	352.12	374.06
Total Revenue	276.09	281.61	262.70
PAT	10.50	3.63	-2.11
EBITDA	61.05	58.76	56.31
Net Worth	96.39	66.29	62.88
Reserves and Surplus	67.56	39.46	36.05
Total Borrowing	195	205.23	215.66

 

Cash Flows

The cash flows for various activities are shown below:

(Amount in millions)

Net Cash Flow In Multiple Activities	31 Mar 2025	31 Mar 2024	31 Mar 2023
Net Cash Flow Operating Activities	4,662.00	5,807.30	4,258.04
Net Cash Flow Investing Activities	(2,447.25)	(1,032.09)	(653.19)
Net Cash Flow Financing Activities	(2,346.63)	(4,632.38)	(4,232.07)

 

Revenue Bifurcation 

Business-wise Revenue Breakdown

Geography-wise Revenue Breakdown

State-wise Revenue Breakdown

(Source RHP)

The Objective of The Issue

• Financing the necessary capital expenditures for civil construction projects, as well as the acquisition of machinery, equipment, and plant for the establishment of a new SteriPort production line in Gujarat. ~ Rs. 70 Cr.

• Covering the necessary capital expenditures for civil construction projects and the acquisition of machinery, plant, and equipment to establish a new SVP manufacturing line. ~ Rs. 30.13 Cr.

• General corporate purposes.

Click to check the IPO application status.

Listed Peers of Amanta Healthcare Ltd.

Company Name	Face Value (Rs. per Share)	EPS (Rs.)	P/E (x)
Denis Chem Lab Limited	10	5.82	15.92

Listed Peer Analysis

Valuation

Metric	Value
ROE%	12.42%
ROCE	13.72%
Debt/Equity	2.02
PAT Margin	3.86%
EBITDA	22.11%
Price to Book Value	3.77
RoNW	10.89%

 

 

 

Evaluation of P/E Ratio

Considering the period of FY 2025, with an EPS of Rs. 3.71 from the last year, the resulting P/E ratio is 33.96x. When compared with the industry’s average P/E of 15.92x, it indicates an overvaluation (on a P/E ratio basis only). Hence, the price of the Share seems aggressively priced for the investors.

Explore the Vikran Engineering IPO.

IPO's Strengths

• A reputable pharmaceutical formulation maker with a wide range of products and a varied clientele.

• Large-scale production capacity

• An extensive network of domestic and foreign marketers

• Seasoned executive group backed by a sizable, varied, and competent workforce.

 

IPO’s Weaknesses 

• Reliance upon Imports.

• Foreign exchange fluctuations.

• Adherence to US FDA guidelines.

• Policy and regulatory obstacles.

 

Amanta Healthcare IPO GMP 

Amanta Healthcare IPO GMP today is Rs. 22 as of 26 Aug 2025, while writing this information. Hence, the Amanta Healthcare IPO listing price (estimated) might be Rs. 148 (upper price + current GMP or grey market premium).

Amanta Healthcare Limited IPO Summary

IPO Opening & Closing Date	Sep 01, 2025 to Sep 03, 2025
Face Value	Rs. 10 per Share
Issue Price	Rs. 120 to Rs. 126
Lot Size	119 Shares
Issue Size	1,00,00,000 Shares (Rs. 126 Cr)
Offer for Sale	-
Fresh Issue	1,00,00,000 Shares (Rs. 126 Cr)
Listing At	BSE, NSE
Issue Type	Book Built Issue IPO
Registrar	MUFG Intime India Pvt. Ltd.

 

 

Amanta Healthcare IPO Lot Size

The IPO allows retail investors to invest in a minimum and maximum of 1 Lot (119 Shares) amounting to Rs. 14994 and 13 Lots (1547 Shares) amounting to Rs. 194922, respectively, while for S-HNI investors, the minimum Lot is 14 (1666 Shares) amounting to Rs. 209916.

Minimum Lot Investment (Retail)	1 Lot
Maximum Lot Investment (Retail)	13 Lots
SHNI (Minimum)	14 Lots
SHNI (Maximum)	66 Lots
BHNI (Minimum)	67 Lots

 

Amanta Healthcare IPO Reservation

Institutional Share Portion	50%
Retail Investors' Share Portion	35%
Non-Institutional Shares Portion	15%

 

Amanta Healthcare IPO Allotment Status

To check the Amanta Healthcare IPO allotment status, visit the official Registrar’s website or the BSE website. Below are the website links for you.

Using Registrar’s Website - Link Intime IPO allotment status

Using BSE Website - ​BSE IPO allotment status

 

Promoters And Management of Amanta Healthcare Ltd.

• Bhavesh Patel

• Vishal Patel

• Jayshreeben Patel

• Jitendra Kumar Patel

• Milcent Appliances Private Limited.

Pre-Issue Promoter Shareholding	85.60%
Post-Issue Promoter Shareholding	63.56%

 

Amanta Healthcare IPO Lead Managers

• Beeline Capital Advisors Pvt.Ltd.   

 

Dividend Policy

The company has paid a dividend of Rs. 0.99, Rs. 1.00, and Rs. 0.50 during the last three fiscal years.

Conclusion

The Amanta Healthcare IPO gives investors an opportunity to get into the expanding medical device and sterile liquid markets in India and globally. Despite the company's strong production capacity, diverse product range, and seasoned management, investors should be mindful of its hidden debt, promoter pledges, and dependence on significant international clients. The IPO is priced aggressively in comparison to its industry peers, with a P/E ratio of 33.96x, indicating that cautious analysis is necessary.

 

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.

Finowings IPO Analysis

Hope you enjoyed the Finowings IPO Analysis. We tried our best to give every required detail about the company that you should know before applying to the IPO. 

You must consult your financial advisor before making any financial decisions. 

To Apply for the IPO, Click Here.

To Read the Prospectus of the Company Click Here to Download the DRHP.

Click Here To Stay Updated With The Upcoming IPOs.

DISCLAIMER: This blog is NOT any buy or sell recommendation. No investment or trading advice is given. The content is purely for educational and information purposes only. Always consult your eligible financial advisor for investment-related decisions.